Chemotherapy in cancer patients with Covid-19 ‘not a risk’

0
201

Continuing chemotherapy and immunotherapy treatment in cancer patients with Covid-19 isn’t a risk to their survival, a study suggests.

It also recommends further research into the drug hydroxychloroquine, which seemed to benefit some patients. The findings, from 890 infected cancer patients in the UK, Spain, Italy, and Germany, could help identify who is most in danger from coronavirus.

They are also keen to research why UK cancer patients with Covid-19 in the study were more likely to die than in the three other countries. ‘Cancer treatment could also be safe’

The pandemic has had an impression on patients’ access to cancer treatments, and in some cases, it’s been postponed or stopped altogether supported little or no “solid evidence”, he said.

Treatments like chemotherapy and immunotherapy didn’t seem to extend mortality risk from Covid-19, he added.

Breast cancer query
In the study, one in three cancer patients with Covid-19 had died between the top of February and therefore the start of April.

Men, the over-65s, and people with other health conditions fared worse than other cancer patients with the virus – an equivalent risk factors for the overall population.

But women with carcinoma seemed to be protected, to some extent, altogether four countries. Their death rate was only 15%.

53% were receiving therapy, of whom 1/4 were having chemotherapy
45% weren’t on any treatment
About 80% of them had caught the virus within the community.

According to the researchers, the study’s findings might be to compute which cancer patients were most vulnerable and will be shielding to guard themselves from the virus.

They also said more clinical trials into emerging Covid-19 treatments in infected cancer patients, like hydroxychloroquine, needed to happen soon.

The anti-malarial drug has been the topic of controversy after two studies were retracted recently. They suggested the drug might worsen mortality.

LEAVE A REPLY

Please enter your comment!
Please enter your name here